{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:37:41Z","timestamp":1793860661441,"version":"4.6.1"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:00:00Z","timestamp":1746316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:00:00Z","timestamp":1746316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"China Health Commission of Sichuan Province Medical Science and Technology Program","award":["23LCYJ004"],"award-info":[{"award-number":["23LCYJ004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06184-z","type":"journal-article","created":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T10:08:04Z","timestamp":1746353284000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["PSMA PET\/CT for prostate cancer diagnosis: current applications and future directions"],"prefix":"10.1007","volume":"151","author":[{"given":"Zhengang","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu Zhong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-7165","authenticated-orcid":false,"given":"Hong","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6319-723X","authenticated-orcid":false,"given":"Shukui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,4]]},"reference":[{"key":"6184_CR1","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s00259-023-06438-3","volume":"51","author":"S Adebahr","year":"2024","unstructured":"Adebahr S, Althaus A, Scharl S et al (2024) The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy. Eur J Nucl Med Mol Imaging 51:558\u2013567. https:\/\/doi.org\/10.1007\/s00259-023-06438-3","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6184_CR2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/MNM.0000000000001370","volume":"42","author":"A Aksu","year":"2021","unstructured":"Aksu A, Karahan \u015een NP, Tuna EB, Aslan G, \u00c7apa Kaya G (2021) Evaluation of 68ga-PSMA PET\/CT with volumetric parameters for staging of prostate cancer patients. Nucl Med Commun 42:503\u2013509. https:\/\/doi.org\/10.1097\/MNM.0000000000001370","journal-title":"Nucl Med Commun"},{"key":"6184_CR3","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1007\/s00259-021-05456-3","volume":"48","author":"EG Arnfield","year":"2021","unstructured":"Arnfield EG, Thomas PA, Roberts MJ et al (2021) Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation. Eur J Nucl Med Mol Imaging 48:4495\u20134507. https:\/\/doi.org\/10.1007\/s00259-021-05456-3","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6184_CR4","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.2217\/fon-2020-1293","volume":"17","author":"D Bagguley","year":"2021","unstructured":"Bagguley D, Ong S, Buteau JP et al (2021) Role of PSMA PET\/CT imaging in the diagnosis, staging and restaging of prostate cancer. Future Oncol 17:2225\u20132241. https:\/\/doi.org\/10.2217\/fon-2020-1293","journal-title":"Future Oncol"},{"key":"6184_CR5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/JU.0000000000004032","volume":"212","author":"CD Bahler","year":"2024","unstructured":"Bahler CD, Tachibana I, Tann M et al (2024) Comparing magnetic resonance imaging and prostate-specific membrane antigen-positron emission tomography for prediction of extraprostatic extension of prostate cancer and surgical guidance: a prospective nonrandomized clinical trial. J Urol 212:290\u2013298. https:\/\/doi.org\/10.1097\/JU.0000000000004032","journal-title":"J Urol"},{"key":"6184_CR6","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/MOU.0000000000001118","volume":"33","author":"F Barletta","year":"2023","unstructured":"Barletta F, Ceci F, van den Bergh RCN et al (2023) The role of nuclear medicine tracers for prostate cancer surgery: from preoperative to intraoperative setting. Curr Opin Urol 33:502\u2013509. https:\/\/doi.org\/10.1097\/MOU.0000000000001118","journal-title":"Curr Opin Urol"},{"key":"6184_CR7","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/bju.16167","volume":"132","author":"YJL Bodar","year":"2023","unstructured":"Bodar YJL, Boev\u00e9 LMS, van Leeuwen PJ et al (2023) Using prostate-specific membrane antigen positron-emission tomography to guide prostate biopsies and stage men at high risk of prostate cancer. BJU Int 132:705\u2013712. https:\/\/doi.org\/10.1111\/bju.16167","journal-title":"BJU Int"},{"key":"6184_CR8","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1007\/s00330-018-5751-1","volume":"29","author":"D Bonekamp","year":"2019","unstructured":"Bonekamp D, Schelb P, Wiesenfarth M et al (2019) Histopathological to multiparametric MRI Spatial mapping of extended systematic sextant and MR\/TRUS-fusion-targeted biopsy of the prostate. Eur Radiol 29:1820\u20131830. https:\/\/doi.org\/10.1007\/s00330-018-5751-1","journal-title":"Eur Radiol"},{"key":"6184_CR9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.eururo.2015.06.010","volume":"69","author":"L Bud\u00e4us","year":"2016","unstructured":"Bud\u00e4us L, Leyh-Bannurah S-R, Salomon G et al (2016) Initial experience of (68)Ga-PSMA PET\/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol 69:393\u2013396. https:\/\/doi.org\/10.1016\/j.eururo.2015.06.010","journal-title":"Eur Urol"},{"key":"6184_CR10","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/s41379-019-0408-4","volume":"33","author":"LC Cahill","year":"2020","unstructured":"Cahill LC, Wu Y, Yoshitake T et al (2020) Nonlinear microscopy for detection of prostate cancer: analysis of sensitivity and specificity in radical prostatectomies. Mod Pathol 33:916\u2013923. https:\/\/doi.org\/10.1038\/s41379-019-0408-4","journal-title":"Mod Pathol"},{"key":"6184_CR11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40336-020-00372-2","volume":"8","author":"S Carrilho Vaz","year":"2020","unstructured":"Carrilho Vaz S, Silva \u00c2, Oliveira C et al (2020) Impact of PSMA PET\/CT in prostate cancer patient\u2019s clinical management: a pictorial essay of interesting cases with histologic confirmation. Clin Transl Imaging 8:207\u2013226. https:\/\/doi.org\/10.1007\/s40336-020-00372-2","journal-title":"Clin Transl Imaging"},{"key":"6184_CR12","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.3390\/diagnostics13162697","volume":"13","author":"L Cereser","year":"2023","unstructured":"Cereser L, Evangelista L, Giannarini G, Girometti R (2023) Prostate MRI and PSMA-PET in the primary diagnosis of prostate cancer. Diagnostics (Basel) 13:2697. https:\/\/doi.org\/10.3390\/diagnostics13162697","journal-title":"Diagnostics (Basel)"},{"key":"6184_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40644-022-00456-4","volume":"22","author":"Z Chen","year":"2022","unstructured":"Chen Z, Chen X, Wang R (2022) Application of SPECT and PET \/ CT with computer-aided diagnosis in bone metastasis of prostate cancer: a review. Cancer Imaging 22:18. https:\/\/doi.org\/10.1186\/s40644-022-00456-4","journal-title":"Cancer Imaging"},{"key":"6184_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","volume":"84","author":"KM Chow","year":"2023","unstructured":"Chow KM, So WZ, Lee HJ et al (2023) Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for initial staging of intermediate- to high-risk prostate cancer: A systematic review and meta-analysis. Eur Urol 84:36\u201348. https:\/\/doi.org\/10.1016\/j.eururo.2023.03.001","journal-title":"Eur Urol"},{"key":"6184_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/diagnostics12010195","volume":"12","author":"MT Christensen","year":"2022","unstructured":"Christensen MT, Jochumsen MR, Klingenberg S et al (2022) Evaluation of predictors of biochemical recurrence in prostate cancer patients, as detected by 68ga-PSMA PET\/CT. Diagnostics (Basel) 12:195. https:\/\/doi.org\/10.3390\/diagnostics12010195","journal-title":"Diagnostics (Basel)"},{"key":"6184_CR16","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1053\/j.semnuclmed.2021.11.013","volume":"52","author":"A Daryanani","year":"2022","unstructured":"Daryanani A, Turkbey B (2022) Recent advancements in CT and MR imaging of prostate cancer. Semin Nucl Med 52:365\u2013373. https:\/\/doi.org\/10.1053\/j.semnuclmed.2021.11.013","journal-title":"Semin Nucl Med"},{"key":"6184_CR17","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.eururo.2022.05.010","volume":"82","author":"K De Man","year":"2022","unstructured":"De Man K, Van Laeken N, Schelfhout V et al (2022) 18F-PSMA-11 versus 68Ga-PSMA-11 positron emission tomography\/computed tomography for staging and biochemical recurrence of prostate cancer: a prospective double-blind randomised cross-over trial. Eur Urol 82:501\u2013509. https:\/\/doi.org\/10.1016\/j.eururo.2022.05.010","journal-title":"Eur Urol"},{"key":"6184_CR18","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2967\/jnumed.116.185538","volume":"58","author":"F Dietlein","year":"2017","unstructured":"Dietlein F, Kobe C, Neubauer S et al (2017) PSA-stratified performance of 18F- and 68Ga-PSMA PET in patients with biochemical recurrence of prostate cancer. J Nucl Med 58:947\u2013952. https:\/\/doi.org\/10.2967\/jnumed.116.185538","journal-title":"J Nucl Med"},{"key":"6184_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41391-023-00708-9","volume":"27","author":"F Ditonno","year":"2024","unstructured":"Ditonno F, Franco A, Manfredi C et al (2024) Novel non-MRI imaging techniques for primary diagnosis of prostate cancer: micro-ultrasound, contrast-enhanced ultrasound, elastography, multiparametric ultrasound, and PSMA PET\/CT. Prostate Cancer Prostatic Dis 27:29\u201336. https:\/\/doi.org\/10.1038\/s41391-023-00708-9","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"6184_CR20","doi-asserted-by":"publisher","first-page":"845","DOI":"10.2967\/jnumed.111.098608","volume":"53","author":"A Drzezga","year":"2012","unstructured":"Drzezga A, Souvatzoglou M, Eiber M et al (2012) First clinical experience with integrated whole-body PET\/MR: comparison to PET\/CT in patients with oncologic diagnoses. J Nucl Med 53:845\u2013855. https:\/\/doi.org\/10.2967\/jnumed.111.098608","journal-title":"J Nucl Med"},{"key":"6184_CR21","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/pros.24538","volume":"83","author":"I Duncan","year":"2023","unstructured":"Duncan I, Ingold N, Martinez-Marroquin E, Paterson C (2023) An Australian experience using Tc\u2010PSMA SPECT\/CT in the primary diagnosis of prostate cancer and for staging at biochemical recurrence after local therapy. Prostate 83:970\u2013979. https:\/\/doi.org\/10.1002\/pros.24538","journal-title":"Prostate"},{"key":"6184_CR22","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s00345-018-2524-z","volume":"37","author":"RS Eapen","year":"2019","unstructured":"Eapen RS, Nzenza TC, Murphy DG et al (2019) PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics. World J Urol 37:1255\u20131261. https:\/\/doi.org\/10.1007\/s00345-018-2524-z","journal-title":"World J Urol"},{"issue":"Supplement 2","key":"6184_CR23","doi-asserted-by":"publisher","first-page":"67S","DOI":"10.2967\/jnumed.116.186767","volume":"58","author":"M Eiber","year":"2017","unstructured":"Eiber M, Fendler WP, Rowe SP et al (2017) Prostate-specific membrane antigen ligands for imaging and therapy. J Nucl Med 58(Supplement 2):67S\u201376S. https:\/\/doi.org\/10.2967\/jnumed.116.186767","journal-title":"J Nucl Med"},{"key":"6184_CR24","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J et al (2018) Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed MiTNM classification for the interpretation of PSMA-ligand PET\/CT. J Nucl Med 59:469\u2013478. https:\/\/doi.org\/10.2967\/jnumed.117.198119","journal-title":"J Nucl Med"},{"key":"6184_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.euo.2022.03.004","volume":"5","author":"L Evangelista","year":"2022","unstructured":"Evangelista L, Maurer T, van der Poel H et al (2022) [68Ga]Ga-PSMA versus [18F]PSMA positron emission tomography\/computed tomography in the staging of primary and recurrent prostate cancer. A systematic review of the literature. Eur Urol Oncol 5:273\u2013282. https:\/\/doi.org\/10.1016\/j.euo.2022.03.004","journal-title":"Eur Urol Oncol"},{"key":"6184_CR27","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.7150\/thno.44584","volume":"10","author":"DA Ferraro","year":"2020","unstructured":"Ferraro DA, R\u00fcschoff JH, Muehlematter UJ et al (2020) Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with 68Ga-PSMA-11-PET. Theranostics 10:6082\u20136094. https:\/\/doi.org\/10.7150\/thno.44584","journal-title":"Theranostics"},{"key":"6184_CR28","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1007\/s00259-022-05882-x","volume":"49","author":"A Gafita","year":"2022","unstructured":"Gafita A, Rauscher I, Fendler WP et al (2022) Measuring response in metastatic castration-resistant prostate cancer using PSMA PET\/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. Eur J Nucl Med Mol Imaging 49:4271\u20134281. https:\/\/doi.org\/10.1007\/s00259-022-05882-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6184_CR29","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s12094-022-03002-7","volume":"25","author":"A Gawish","year":"2023","unstructured":"Gawish A, Abdullayev N, El-Arayedh S et al (2023) Metabolic response after 68Ga-PSMA-PET\/CT-directed IGRT\/SBRT for oligometastases prostate cancer. Clin Transl Oncol 25:987\u2013994. https:\/\/doi.org\/10.1007\/s12094-022-03002-7","journal-title":"Clin Transl Oncol"},{"key":"6184_CR30","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1007\/s00259-023-06287-0","volume":"50","author":"F Gelardi","year":"2023","unstructured":"Gelardi F, Briganti A, Pini C et al (2023) European guidelines update on PSMA PET\/CT for prostate cancer staging-snap back to reality. Eur J Nucl Med Mol Imaging 50:2572\u20132575. https:\/\/doi.org\/10.1007\/s00259-023-06287-0","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6184_CR31","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2967\/jnumed.117.196329","volume":"59","author":"FL Giesel","year":"2018","unstructured":"Giesel FL, Will L, Kesch C et al (2018) Biochemical recurrence of prostate cancer: initial results with [18F]PSMA-1007 PET\/CT. J Nucl Med 59:632\u2013635. https:\/\/doi.org\/10.2967\/jnumed.117.196329","journal-title":"J Nucl Med"},{"key":"6184_CR32","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.2967\/jnumed.121.263139","volume":"63","author":"MJ Hagens","year":"2022","unstructured":"Hagens MJ, Oprea-Lager DE, Vis AN et al (2022) Reproducibility of PSMA PET\/CT imaging for primary staging of treatment-na\u00efve prostate cancer patients depends on the applied radiotracer: A retrospective study. J Nucl Med 63:1531\u20131536. https:\/\/doi.org\/10.2967\/jnumed.121.263139","journal-title":"J Nucl Med"},{"key":"6184_CR33","doi-asserted-by":"publisher","first-page":"540","DOI":"10.2967\/jnumed.119.232199","volume":"61","author":"FJ Hinsenveld","year":"2020","unstructured":"Hinsenveld FJ, Wit EMK, van Leeuwen PJ et al (2020) Prostate-specific membrane antigen PET\/CT combined with Sentinel node biopsy for primary lymph node staging in prostate cancer. J Nucl Med 61:540\u2013545. https:\/\/doi.org\/10.2967\/jnumed.119.232199","journal-title":"J Nucl Med"},{"key":"6184_CR34","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13550-021-00845-z","volume":"11","author":"S Hober\u00fcck","year":"2021","unstructured":"Hober\u00fcck S, L\u00f6ck S, Borkowetz A et al (2021) Intraindividual comparison of [68 ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis. EJNMMI Res 11:109. https:\/\/doi.org\/10.1186\/s13550-021-00845-z","journal-title":"EJNMMI Res"},{"key":"6184_CR35","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.3390\/cancers12102788","volume":"12","author":"MA Hoffmann","year":"2020","unstructured":"Hoffmann MA, Buchholz H-G, Wieler HJ et al (2020) Dual-Time point [68Ga]Ga-PSMA-11 PET\/CT hybrid imaging for staging and restaging of prostate cancer. Cancers 12:2788. https:\/\/doi.org\/10.3390\/cancers12102788","journal-title":"Cancers"},{"key":"6184_CR36","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395:1208\u20131216. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7","journal-title":"Lancet"},{"key":"6184_CR37","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.2967\/jnumed.121.263441","volume":"63","author":"M Hotta","year":"2022","unstructured":"Hotta M, Gafita A, Czernin J, Calais J (2022) Outcome of patients with PSMA PET\/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: A multicenter retrospective analysis. J Nucl Med 63:1484\u20131488. https:\/\/doi.org\/10.2967\/jnumed.121.263441","journal-title":"J Nucl Med"},{"key":"6184_CR38","doi-asserted-by":"publisher","unstructured":"Huang S, Ong S, McKenzie D et al (2023) Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET\/CT imaging of prostate cancer\u2014a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 1\u201311. https:\/\/doi.org\/10.1038\/s41391-023-00755-2","DOI":"10.1038\/s41391-023-00755-2"},{"key":"6184_CR39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13550-022-00918-7","volume":"12","author":"J Ingvar","year":"2022","unstructured":"Ingvar J, Hvittfeldt E, Tr\u00e4g\u00e5rdh E, Simoulis A, Bjartell A (2022) Assessing the accuracy of [18F]PSMA-1007 PET\/CT for primary staging of lymph node metastases in intermediate- and high-risk prostate cancer patients. EJNMMI Res 12:48. https:\/\/doi.org\/10.1186\/s13550-022-00918-7","journal-title":"EJNMMI Res"},{"key":"6184_CR40","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1053\/j.semnuclmed.2023.02.006","volume":"53","author":"V Jeet","year":"2023","unstructured":"Jeet V, Parkinson B, Song R, Sharma R, Hoyle M (2023) Histopathologically validated diagnostic accuracy of PSMA-PET\/CT in the primary and secondary staging of prostate cancer and the impact of PSMA-PET\/CT on clinical management: a systematic review and meta-analysis. Semin Nucl Med 53:706\u2013718. https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.02.006","journal-title":"Semin Nucl Med"},{"key":"6184_CR25","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3390\/diagnostics12020426","volume":"12","author":"S Katal","year":"2022","unstructured":"Katal S, Eibschutz LS, Saboury B, Gholamrezanezhad A, Alavi A (2022) Advantages and applications of total-body PET scanning. Diagn (Basel Switz) 12:426. https:\/\/doi.org\/10.3390\/diagnostics12020426","journal-title":"Diagn (Basel Switz)"},{"key":"6184_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-07060-7","author":"D Kersting","year":"2025","unstructured":"Kersting D, Borys K, K\u00fcper A et al (2025) Staging of prostate cancer with ultra-fast PSMA-PET scans enhanced by AI. Eur J Nucl Med Mol Imaging. https:\/\/doi.org\/10.1007\/s00259-024-07060-7","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6184_CR42","doi-asserted-by":"publisher","first-page":"111774","DOI":"10.1016\/j.ejrad.2024.111774","volume":"181","author":"F Kleiburg","year":"2024","unstructured":"Kleiburg F, de Geus-Oei LF, Luelmo SAC et al (2024) PSMA PET\/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients. Eur J Radiol 181:111774. https:\/\/doi.org\/10.1016\/j.ejrad.2024.111774","journal-title":"Eur J Radiol"},{"key":"6184_CR43","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2967\/jnumed.119.234187","volume":"61","author":"J Kuten","year":"2020","unstructured":"Kuten J, Fahoum I, Savin Z et al (2020) Head-to-head comparison of 68ga-PSMA-11 with 18F-PSMA-1007 PET\/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard. J Nucl Med 61:527\u2013532. https:\/\/doi.org\/10.2967\/jnumed.119.234187","journal-title":"J Nucl Med"},{"key":"6184_CR44","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.eururo.2014.08.079","volume":"67","author":"JD Le","year":"2015","unstructured":"Le JD, Tan N, Shkolyar E et al (2015) Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Eur Urol 67:569\u2013576. https:\/\/doi.org\/10.1016\/j.eururo.2014.08.079","journal-title":"Eur Urol"},{"key":"6184_CR45","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.2967\/jnumed.119.235333","volume":"61","author":"C Liu","year":"2020","unstructured":"Liu C, Liu T, Zhang Z et al (2020) 68ga-PSMA PET\/CT combined with PET\/ultrasound-guided prostate biopsy can diagnose clinically significant prostate cancer in men with previous negative biopsy results. J Nucl Med 61:1314\u20131319. https:\/\/doi.org\/10.2967\/jnumed.119.235333","journal-title":"J Nucl Med"},{"key":"6184_CR46","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3390\/cancers16030486","volume":"16","author":"J Liu","year":"2024","unstructured":"Liu J, Cundy TP, Woon DTS, Lawrentschuk N (2024) A systematic review on artificial intelligence evaluating metastatic prostatic cancer and lymph nodes on PSMA PET scans. Cancers 16:486. https:\/\/doi.org\/10.3390\/cancers16030486","journal-title":"Cancers"},{"key":"6184_CR47","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2024.12.001","author":"J Liu","year":"2025","unstructured":"Liu J, Sandhu K, Woon DTS, Perera M, Lawrentschuk N (2025) The value of artificial intelligence in prostate-specific membrane antigen positron emission tomography: an update. Semin Nucl Med:S. https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.12.001. 0001-2998(24)00120-X","journal-title":"Semin Nucl Med:S"},{"key":"6184_CR48","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3390\/diagnostics11010117","volume":"11","author":"WI Luining","year":"2021","unstructured":"Luining WI, Meijer D, Dahele MR, Vis AN, Oprea-Lager DE (2021) Nuclear imaging for bone metastases in prostate cancer: the emergence of modern techniques using novel radiotracers. Diagnostics (Basel) 11:117. https:\/\/doi.org\/10.3390\/diagnostics11010117","journal-title":"Diagnostics (Basel)"},{"key":"6184_CR50","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.3390\/molecules27123862","volume":"27","author":"C Maisto","year":"2022","unstructured":"Maisto C, Aurilio M, Morisco A et al (2022) Analysis of pros and cons in using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007: production, costs, and PET\/CT applications in patients with prostate cancer. Molecules 27:3862. https:\/\/doi.org\/10.3390\/molecules27123862","journal-title":"Molecules"},{"key":"6184_CR51","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1007\/s00259-021-05296-1","volume":"48","author":"S Malaspina","year":"2021","unstructured":"Malaspina S, Anttinen M, Taimen P et al (2021) Prospective comparison of 18F-PSMA-1007 PET\/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer. Eur J Nucl Med Mol Imaging 48:2951\u20132959. https:\/\/doi.org\/10.1007\/s00259-021-05296-1","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6184_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-07065-2","author":"Q Ma","year":"2025","unstructured":"Ma Q, Chen B, Seifert R et al (2025) PSMA PET\/CT based multimodal deep learning model for accurate prediction of pelvic lymph-node metastases in prostate cancer patients identified as candidates for extended pelvic lymph node dissection by preoperative nomograms. Eur J Nucl Med Mol Imaging. https:\/\/doi.org\/10.1007\/s00259-024-07065-2","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6184_CR52","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","volume":"195","author":"T Maurer","year":"2016","unstructured":"Maurer T, Gschwend JE, Rauscher I et al (2016) Diagnostic efficacy of (68)gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol 195:1436\u20131443. https:\/\/doi.org\/10.1016\/j.juro.2015.12.025","journal-title":"J Urol"},{"key":"6184_CR53","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3390\/jcm13020446","volume":"13","author":"EL McKone","year":"2024","unstructured":"McKone EL, Sutton EA, Johnson GB, Phillips RM (2024) Application of advanced imaging to prostate cancer diagnosis and management: A narrative review of current practice and unanswered questions. J Clin Med 13:446. https:\/\/doi.org\/10.3390\/jcm13020446","journal-title":"J Clin Med"},{"key":"6184_CR54","doi-asserted-by":"publisher","first-page":"doad034","DOI":"10.1093\/dote\/doad034","volume":"36","author":"N Menon","year":"2023","unstructured":"Menon N, Guidozzi N, Chidambaram S, Markar SR (2023) Performance of radiomics-based artificial intelligence systems in the diagnosis and prediction of treatment response and survival in esophageal cancer: a systematic review and meta-analysis of diagnostic accuracy. Dis Esophagus 36:doad034. https:\/\/doi.org\/10.1093\/dote\/doad034","journal-title":"Dis Esophagus"},{"key":"6184_CR55","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/jamaoncol.2024.3196","volume":"10","author":"N Mookerji","year":"2024","unstructured":"Mookerji N, Pfanner T, Hui A et al (2024) Fluorine-18 prostate-specific membrane antigen-1007 PET\/CT vs multiparametric MRI for locoregional staging of prostate cancer. JAMA Oncol 10:1097\u20131103. https:\/\/doi.org\/10.1001\/jamaoncol.2024.3196","journal-title":"JAMA Oncol"},{"key":"6184_CR56","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13550-022-00885-z","volume":"12","author":"J Morawitz","year":"2022","unstructured":"Morawitz J, Kirchner J, Hertelendy J et al (2022) Is there a diagnostic benefit of late-phase abdomino-pelvic PET\/CT after urination as part of whole-body 68 ga-PSMA-11 PET\/CT for restaging patients with biochemical recurrence of prostate cancer after radical prostatectomy? EJNMMI Res 12:12. https:\/\/doi.org\/10.1186\/s13550-022-00885-z","journal-title":"EJNMMI Res"},{"key":"6184_CR57","doi-asserted-by":"publisher","first-page":"109556","DOI":"10.1016\/j.ejrad.2021.109556","volume":"136","author":"J Morawitz","year":"2021","unstructured":"Morawitz J, Kirchner J, Lakes J et al (2021) PSMA PET\/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: comparison of detection rates and therapeutic implications. Eur J Radiol 136:109556. https:\/\/doi.org\/10.1016\/j.ejrad.2021.109556","journal-title":"Eur J Radiol"},{"key":"6184_CR58","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1148\/radiol.2019190687","volume":"293","author":"UJ Muehlematter","year":"2019","unstructured":"Muehlematter UJ, Burger IA, Becker AS et al (2019) Diagnostic accuracy of multiparametric MRI versus 68ga-PSMA-11 PET\/MRI for extracapsular extension and seminal vesicle invasion in patients with prostate cancer. Radiology 293:350\u2013358. https:\/\/doi.org\/10.1148\/radiol.2019190687","journal-title":"Radiology"},{"key":"6184_CR59","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/iju.13514","volume":"25","author":"Y Murata","year":"2018","unstructured":"Murata Y, Tatsugami K, Yoshikawa M et al (2018) Predictive factors of biochemical recurrence after radical prostatectomy for high-risk prostate cancer. Int J Urol 25:284\u2013289. https:\/\/doi.org\/10.1111\/iju.13514","journal-title":"Int J Urol"},{"key":"6184_CR60","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2214\/AJR.21.26426","volume":"218","author":"A Patra","year":"2022","unstructured":"Patra A, Khasawneh H, Suman G et al (2022) Cal metastases in the abdomen and pelvis from biochemically recurrent prostate cancer. AJR Am J Roentgenol Atypi 218:141\u2013150. https:\/\/doi.org\/10.2214\/AJR.21.26426.:11\u00a0C-Choline PET\/CT With Multimodality Correlation","journal-title":"AJR Am J Roentgenol Atypi"},{"key":"6184_CR61","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13550-020-0593-7","volume":"10","author":"S Piron","year":"2020","unstructured":"Piron S, De Man K, Schelfhout V et al (2020) Optimization of PET protocol and interrater reliability of 18F-PSMA-11 imaging of prostate cancer. EJNMMI Res 10:14. https:\/\/doi.org\/10.1186\/s13550-020-0593-7","journal-title":"EJNMMI Res"},{"key":"6184_CR62","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s13139-022-00754-6","volume":"56","author":"S Probst","year":"2022","unstructured":"Probst S, Bjartell A, Anand A, Skamene T, Ferrario C (2022) Interval changes in PSMA PET\/CT during radium-223 therapy for metastatic bone disease from castration-resistant prostate cancer. Nucl Med Mol Imaging 56:188\u2013195. https:\/\/doi.org\/10.1007\/s13139-022-00754-6","journal-title":"Nucl Med Mol Imaging"},{"key":"6184_CR63","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1097\/MOU.0000000000000799","volume":"30","author":"AS Ravi Kumar","year":"2020","unstructured":"Ravi Kumar AS, Lawrentschuk N, Hofman MS (2020) Prostate-specific membrane antigen PET\/computed tomography for staging prostate cancer. Curr Opin Urol 30:628\u2013634. https:\/\/doi.org\/10.1097\/MOU.0000000000000799","journal-title":"Curr Opin Urol"},{"key":"6184_CR64","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3329\/kyamcj.v13i2.61344","volume":"13","author":"KP Rekha","year":"2022","unstructured":"Rekha KP, Ray DS, Jubaida R, Sharif MM, Hussain M (2022) MDCT detection of omental metastases with peritoneal carcinomatosis and Ascites in prostate cancer: an unusual metastatic site. KYAMC J 13:124\u2013126. https:\/\/doi.org\/10.3329\/kyamcj.v13i2.61344","journal-title":"KYAMC J"},{"key":"6184_CR65","doi-asserted-by":"publisher","unstructured":"Rovera G, Grimaldi S, Oderda M et al (2024) Comparative performance of 68ga-PSMA-11 PET\/CT and conventional imaging in the primary staging of high-risk prostate cancer patients who are candidates for radical prostatectomy. Diagnostics (Basel) 141964. https:\/\/doi.org\/10.3390\/diagnostics14171964","DOI":"10.3390\/diagnostics14171964"},{"key":"6184_CR66","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s40658-023-00587-y","volume":"10","author":"F Sadeghi","year":"2023","unstructured":"Sadeghi F, Sheikhzadeh P, Farzanehfar S et al (2023) The effects of various penalty parameter values in Q.Clear algorithm for rectal cancer detection on 18F-FDG images using a BGO-based PET\/CT scanner: a Phantom and clinical study. EJNMMI Phys 10:63. https:\/\/doi.org\/10.1186\/s40658-023-00587-y","journal-title":"EJNMMI Phys"},{"key":"6184_CR67","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1007\/s00259-019-04308-5","volume":"46","author":"LM Sawicki","year":"2019","unstructured":"Sawicki LM, Kirchner J, Buddensieck C et al (2019) Prospective comparison of whole-body MRI and 68ga-PSMA PET\/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 46:1542\u20131550. https:\/\/doi.org\/10.1007\/s00259-019-04308-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6184_CR68","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.3390\/cancers15082345","volume":"15","author":"R Schollhammer","year":"2023","unstructured":"Schollhammer R, Quintyn Ranty M-L, de Clermont Gallerande H et al (2023) Theranostics of primary prostate cancer: beyond PSMA and GRP-R. Cancers (Basel) 15:2345. https:\/\/doi.org\/10.3390\/cancers15082345","journal-title":"Cancers (Basel)"},{"key":"6184_CR69","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s11307-019-01347-0","volume":"22","author":"Y Seo","year":"2020","unstructured":"Seo Y, Khalighi MM, Wangerin KA et al (2020) Quantitative and qualitative improvement of low-count [68ga]citrate and [90Y]microspheres PET image reconstructions using block sequential regularized expectation maximization algorithm. Mol Imaging Biol 22:208\u2013216. https:\/\/doi.org\/10.1007\/s11307-019-01347-0","journal-title":"Mol Imaging Biol"},{"key":"6184_CR70","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.2967\/jnumed.121.263006","volume":"63","author":"QA Shagera","year":"2022","unstructured":"Shagera QA, Artigas C, Karfis I et al (2022) 68ga-PSMA PET\/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy. J Nucl Med 63:1191\u20131198. https:\/\/doi.org\/10.2967\/jnumed.121.263006","journal-title":"J Nucl Med"},{"key":"6184_CR71","doi-asserted-by":"publisher","first-page":"23","DOI":"10.12954\/PI.12003","volume":"1","author":"AA Shahab","year":"2013","unstructured":"Shahab AA, Soebadi DM, Djatisoesanto W et al (2013) Prostate-specific antigen and prostate-specific antigen density cutoff points among Indonesian population suspected for prostate cancer. Prostate Int 1:23\u201330. https:\/\/doi.org\/10.12954\/PI.12003","journal-title":"Prostate Int"},{"key":"6184_CR72","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s41824-023-00182-5","volume":"7","author":"AP Sharma","year":"2023","unstructured":"Sharma AP, Kumar R, Chauhan R et al (2023) Accuracy of combined multi-parametric MRI and PSMA PET-CT in diagnosing localized prostate cancer: newer horizons for a biopsy-free pathway. Eur J Hybrid Imaging 7:24. https:\/\/doi.org\/10.1186\/s41824-023-00182-5","journal-title":"Eur J Hybrid Imaging"},{"key":"6184_CR73","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17\u201348. https:\/\/doi.org\/10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"key":"6184_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_351033","volume":"42","author":"NI Simon","year":"2022","unstructured":"Simon NI, Parker C, Hope TA, Paller CJ (2022) Best approaches and updates for prostate cancer biochemical recurrence. Am Soc Clin Oncol Educ Book 42:1\u20138. https:\/\/doi.org\/10.1200\/EDBK_351033","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"6184_CR75","doi-asserted-by":"publisher","unstructured":"Soeterik TFW, Heetman JG, Hermsen R et al (2024) The added value of prostate-specific membrane antigen positron emission tomography\/computed tomography to magnetic resonance imaging for local staging of prostate cancer in patients undergoing radical prostatectomy. Eur Urol Oncol S 2588\u20139311. https:\/\/doi.org\/10.1016\/j.euo.2024.11.002. S2588-9311(24)00249-9","DOI":"10.1016\/j.euo.2024.11.002"},{"key":"6184_CR76","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2967\/jnumed.120.250597","volume":"62","author":"BA Spencer","year":"2021","unstructured":"Spencer BA, Berg E, Schmall JP et al (2021) Performance evaluation of the uEXPLORER total-body PET\/CT scanner based on NEMA NU 2\u20132018 with additional tests to characterize PET scanners with a long axial field of view. J Nucl Med 62:861\u2013870. https:\/\/doi.org\/10.2967\/jnumed.120.250597","journal-title":"J Nucl Med"},{"key":"6184_CR77","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1007\/s00259-020-05091-4","volume":"48","author":"H Tan","year":"2021","unstructured":"Tan H, Sui X, Yin H et al (2021) Total-body PET\/CT using half-dose FDG and compared with conventional PET\/CT using full-dose FDG in lung cancer. Eur J Nucl Med Mol Imaging 48:1966\u20131975. https:\/\/doi.org\/10.1007\/s00259-020-05091-4","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6184_CR78","doi-asserted-by":"publisher","first-page":"157","DOI":"10.20892\/j.issn.2095-3941.2018.0288","volume":"16","author":"JSH Tan","year":"2019","unstructured":"Tan JSH, Goh CXY, Koh YS et al (2019) 68 Gallium-labelled PSMA-PET\/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy. Cancer Biol Med 16:157\u2013166. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2018.0288","journal-title":"Cancer Biol Med"},{"key":"6184_CR79","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1089\/02724570050109648","volume":"19","author":"WT Tino","year":"2000","unstructured":"Tino WT, Huber MJ, Lake TP et al (2000) Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA). Hybridoma 19:249\u2013257. https:\/\/doi.org\/10.1089\/02724570050109648","journal-title":"Hybridoma"},{"key":"6184_CR82","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3390\/cancers11050710","volume":"11","author":"G Treglia","year":"2019","unstructured":"Treglia G, Annunziata S, Pizzuto DA et al (2019) Detection rate of 18F-labeled PSMA PET\/CT in biochemical recurrent prostate cancer: A systematic review and a meta-analysis. Cancers (Basel) 11:710. https:\/\/doi.org\/10.3390\/cancers11050710","journal-title":"Cancers (Basel)"},{"key":"6184_CR80","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1007\/s00259-022-05806-9","volume":"49","author":"E Tr\u00e4g\u00e5rdh","year":"2022","unstructured":"Tr\u00e4g\u00e5rdh E, Enqvist O, Ul\u00e9n J et al (2022a) Freely available artificial intelligence for pelvic lymph node metastases in PSMA PET-CT that performs on par with nuclear medicine physicians. Eur J Nucl Med Mol Imaging 49:3412\u20133418. https:\/\/doi.org\/10.1007\/s00259-022-05806-9","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6184_CR81","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.3390\/diagnostics12092101","volume":"12","author":"E Tr\u00e4g\u00e5rdh","year":"2022","unstructured":"Tr\u00e4g\u00e5rdh E, Enqvist O, Ul\u00e9n J et al (2022b) Freely available, fully automated AI-based analysis of primary tumour and metastases of prostate cancer in whole-body [18F]-PSMA-1007 PET-CT. Diagnostics (Basel) 12:2101. https:\/\/doi.org\/10.3390\/diagnostics12092101","journal-title":"Diagnostics (Basel)"},{"key":"6184_CR83","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.1007\/s00259-021-05433-w","volume":"48","author":"MJM Uijen","year":"2021","unstructured":"Uijen MJM, Derks YHW, Merkx RIJ et al (2021) PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports. Eur J Nucl Med Mol Imaging 48:4350\u20134368. https:\/\/doi.org\/10.1007\/s00259-021-05433-w","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6184_CR84","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2967\/jnumed.124.268441","volume":"66","author":"LM Unterrainer","year":"2025","unstructured":"Unterrainer LM, Hope TA, Fendler WP et al (2025) Low- and high-volume disease in metastatic hormone-sensitive prostate cancer: from CHAARTED to PSMA PET-an international multicenter retrospective study. J Nucl Med 66:54\u201360. https:\/\/doi.org\/10.2967\/jnumed.124.268441","journal-title":"J Nucl Med"},{"key":"6184_CR99","doi-asserted-by":"publisher","unstructured":"Vaswani A, Shazeer N, Parmar N et al (2017) Attention is all you need. In: Advances in Neural Information Processing Systems 30 (NeurIPS 2017), pp 5998\u20136008. https:\/\/doi.org\/10.48550\/arXiv.1706.03762","DOI":"10.48550\/arXiv.1706.03762"},{"key":"6184_CR86","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3390\/molecules28031088","volume":"28","author":"A Verena","year":"2023","unstructured":"Verena A, Zhang Z, Kuo H-T et al (2023) Synthesis and preclinical evaluation of three novel 68ga-labeled bispecific PSMA\/FAP-targeting tracers for prostate cancer imaging. Molecules 28:1088. https:\/\/doi.org\/10.3390\/molecules28031088","journal-title":"Molecules"},{"key":"6184_CR87","doi-asserted-by":"publisher","first-page":"1101221","DOI":"10.3389\/fonc.2023.1101221","volume":"13","author":"L Vetrone","year":"2023","unstructured":"Vetrone L, Cuzzani G, Mei R et al (2023) Case report: PSMA PET\/CT addresses the correct diagnosis in a patient with metastatic prostate cancer despite negative core biopsies and MpMRI. A diagnostic challenge. Front Oncol 13:1101221. https:\/\/doi.org\/10.3389\/fonc.2023.1101221","journal-title":"Front Oncol"},{"key":"6184_CR88","doi-asserted-by":"publisher","first-page":"811044","DOI":"10.3389\/fpubh.2022.811044","volume":"10","author":"L Wang","year":"2022","unstructured":"Wang L, Lu B, He M et al (2022) Prostate cancer incidence and mortality: global status and Temporal trends in 89 countries from 2000 to 2019. Front Public Health 10:811044. https:\/\/doi.org\/10.3389\/fpubh.2022.811044","journal-title":"Front Public Health"},{"key":"6184_CR89","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s12149-019-01433-x","volume":"34","author":"E Witkowska-Patena","year":"2020","unstructured":"Witkowska-Patena E, Budzy\u0144ska A, Gi\u017cewska A, Dziuk M, Wal\u0119cka-Mazur A (2020) Ordered subset expectation maximisation vs bayesian penalised likelihood reconstruction algorithm in 18F-PSMA-1007 PET\/CT. Ann Nucl Med 34:192\u2013199. https:\/\/doi.org\/10.1007\/s12149-019-01433-x","journal-title":"Ann Nucl Med"},{"key":"6184_CR90","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12880-024-01376-4","volume":"24","author":"Z Ye","year":"2024","unstructured":"Ye Z, Kou Y, Shen J et al (2024) A comparative study of 18F-PSMA-1007 PET\/CT and pelvic MRI in newly diagnosed prostate cancer. BMC Med Imaging 24:192. https:\/\/doi.org\/10.1186\/s12880-024-01376-4","journal-title":"BMC Med Imaging"},{"key":"6184_CR91","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s12149-021-01594-8","volume":"35","author":"\u00d6A Yildirim","year":"2021","unstructured":"Yildirim \u00d6A, G\u00fcndo\u011fan C, Can C et al (2021) Correlations between whole body volumetric parameters of 68ga-PSMA PET\/CT and biochemical-histopathological parameters in castration-naive and resistant prostate cancer patients. Ann Nucl Med 35:540\u2013548. https:\/\/doi.org\/10.1007\/s12149-021-01594-8","journal-title":"Ann Nucl Med"},{"key":"6184_CR92","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00259-020-04863-2","volume":"48","author":"L-L Zhang","year":"2021","unstructured":"Zhang L-L, Li W-C, Xu Z et al (2021) 68ga-PSMA PET\/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: a prospective randomized single-centre study. Eur J Nucl Med Mol Imaging 48:483\u2013492. https:\/\/doi.org\/10.1007\/s00259-020-04863-2","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6184_CR93","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1007\/s00256-019-03230-z","volume":"48","author":"J Zhou","year":"2019","unstructured":"Zhou J, Gou Z, Wu R et al (2019) Comparison of PSMA-PET\/CT, choline-PET\/CT, NaF-PET\/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis. Skelet Radiol 48:1915\u20131924. https:\/\/doi.org\/10.1007\/s00256-019-03230-z","journal-title":"Skelet Radiol"},{"key":"6184_CR94","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1967\/s002449912525","volume":"25","author":"J Zhou","year":"2022","unstructured":"Zhou J, Wu R, Wang W, Zhao Y, Liu X (2022) 68ga-PSMA PET\/CT for the evaluation of metastasis in patients with prostate cancer: A systematic review and meta-analysis. Hell J Nucl Med 25:297\u2013311. https:\/\/doi.org\/10.1967\/s002449912525","journal-title":"Hell J Nucl Med"},{"key":"6184_CR95","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/onco4010002","volume":"4","author":"M Zirakchian Zadeh","year":"2024","unstructured":"Zirakchian Zadeh M (2024) Significance of PET\/CT imaging in myeloma assessment: exploring novel applications beyond osteolytic lesion detection and treatment response. Onco 4:15\u201336. https:\/\/doi.org\/10.3390\/onco4010002","journal-title":"Onco"},{"key":"6184_CR96","doi-asserted-by":"publisher","first-page":"817","DOI":"10.2967\/jnumed.118.218495","volume":"60","author":"BD Zlatopolskiy","year":"2019","unstructured":"Zlatopolskiy BD, Endepols H, Krapf P et al (2019) Discovery of 18F-JK-PSMA-7, a PET probe for the detection of small PSMA-positive lesions. J Nucl Med 60:817\u2013823. https:\/\/doi.org\/10.2967\/jnumed.118.218495","journal-title":"J Nucl Med"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06184-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06184-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06184-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T06:32:30Z","timestamp":1749537150000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06184-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,4]]},"references-count":96,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["6184"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06184-z","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,4]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"155"}}